Dana Baker
Family · Bridgeville, DENPI 1205354453
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 516 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 516 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$968
- Axsome Therapeutics, Inc.$933
- AbbVie$916
- Alkermes, Inc.$894
- Otsuka America Pharmaceutical, Inc.$864
- Lundbeck LLC$676
- plus $3K from 26 others
What the payments were for
- Food & beverage$8,35899%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $968 |
| Axsome Therapeutics, Inc. | 58 | $933 |
| AbbVie | 64 | $916 |
| Alkermes, Inc. | 38 | $894 |
| Otsuka America Pharmaceutical, Inc. | 72 | $864 |
| Lundbeck LLC | 51 | $676 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $614 |
| Novo Nordisk | 24 | $405 |
| Neurocrine Biosciences, Inc. | 16 | $351 |
| Johnson & Johnson | 10 | $229 |
| Sunovion Pharmaceuticals Inc. | 17 | $217 |
| E.r. Squibb & Sons, L.L.C. | 13 | $164 |
| Lilly USA, LLC | 9 | $161 |
| Vanda Pharmaceuticals Inc. | 8 | $147 |
| Bausch Health US, LLC | 8 | $133 |
| Astellas Pharma US Inc | 2 | $104 |
| Avanir Pharmaceuticals, Inc. | 7 | $92 |
| Exact Sciences | 4 | $75 |
| Idorsia Pharmaceuticals US Inc | 4 | $66 |
| Collegium Pharmaceutical, Inc. | 4 | $66 |
| Pfizer | 3 | $64 |
| Supernus Pharmaceuticals, Inc. | 4 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Indivior Inc. | 2 | $47 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Tris Pharma Inc | 2 | $31 |
| Braeburn Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Bayer | 1 | $16 |
| Abbott | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Corium, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,448 in reported general payments places this provider in the 95th percentile of 523 family providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $74,483 |
| MounjaroTirzepatide | 50 | $59,433 |
| RexultiBrexpiprazole | 14 | $30,057 |
| TrintellixVortioxetine Hydrobromide | 16 | $14,534 |
| EliquisApixaban | 13 | $13,328 |
| XareltoRivaroxaban | 16 | $11,788 |
| JardianceEmpagliflozin | 17 | $9,923 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,505 |
| Duloxetine Hcl | 31 | $1,264 |
| Atorvastatin Calcium | 96 | $997 |
| Gabapentin | 42 | $781 |
| Omeprazole | 37 | $735 |
| Lisinopril | 96 | $654 |
| Rosuvastatin Calcium | 52 | $576 |
| Famotidine | 53 | $467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $405 | $74,48349 claims |
| Lilly USA, LLCMounjaro | $161 | $59,43350 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $864 | $30,05714 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $968 | $14,53416 claims |
| PfizerEliquis | $64 | $13,32813 claims |
| Johnson & JohnsonXarelto | $229 | $11,78816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 523 family providers in Delaware.
Other family in Bridgeville
- Valerie HarrisonBridgeville$15K
- Brandi GreggeMiddletown$110K
- Tracy EstesWilmington$59K
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Abby AllenGeorgetown$43K
- Taylor HodgesLewes$33K
- Jodi KahanWilmington$21K
- Kathleen GustafsonBear$15K
- Elizabeth Sharp-AsiyoWilmington$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.